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K. Śpiewak1 · M. Brindell1 
Received: 6 January 2015 / Accepted: 26 February 2015 / Published online: 20 March 2015 
© The Author(s) 2015. This article is published with open access at Springerlink.com
Keywords Transferrin · Albumin · Serum · NAMI-A · 
FPLC
Introduction
Ru(III) complexes have promptly become an attrac-
tive alternative for the investigation of new metal-based 
anticancer agents [1–3]. One of the most promising drug 
candidates is (ImH)[trans-RuCl4(dmso)(Im)] (NAMI-
A, Fig. 1a, where Im is imidazole), which successfully 
completed phase I clinical trial [4]. Interestingly, in most 
of in vitro and in vivo studies, NAMI-A was inactive as 
cytotoxic agent, however, exhibited a pronounced anti-
metastatic activity [5–8]. Moreover, very recent findings 
suggest that NAMI-A is not internalized into cells and 
consequently, it acts at an extracellular level [9]. Lately, 
quite surprisingly, the high cytotoxicity of NAMI-A 
against a few leukaemia cells was demonstrated but still 
the uptake of Ru complex was marginal and the inhibi-
tion of KCa 3.1 channels was proposed as a mode of 
action [10]. In view of these outcomes, the hypothesis 
that NAMI-A can be transported via transferrin recep-
tor-mediated endocytosis pathway, proposed by many 
researchers [11–15] seems to be questionable. Though 
another hypothesis can be proposed that ruthenated trans-
ferrin can block the transferrin receptor (TfR) and by this 
can decrease the iron transport into cell. This hypoth-
esis has never been closely inspected. The fundamental 
enquiry regards evaluation of the ability of NAMI-A to 
bind to transferrin (Tf) as a natural consequence of intra-
venous injection, despite a huge excess of albumin in 
serum (HSA). Typically, in healthy individuals, the con-
centration of HSA is ca. 0.6 mM [16, 17] while Tf varies 
between 25 and 50 µM [18].
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The Tf is a monomeric glycoprotein (80 kDa) consisted 
of two lobes: N- and C-lobe connected by a short peptide 
linker (Fig. 1b). Tf binds two Fe3+ ions in association 
with the binding of an anion, mostly bicarbonate. Each 
lobe binds iron tightly but reversibly with association 
constant ca. 1022 M−1 [19]. Both iron-binding sites are 
identical (two tyrosines, a histidine and an aspartic acid). 
Only 30 % of Tf exists as iron-saturated diferric form of 
Tf (holo-Tf) [18]. Holo-Tf binds to the TfR located on 
the outer cell membrane with a high affinity (nanomolar 
dissociation constant) at neutral pH (~7.4) [20], while 
the iron-free form of Tf (apo-Tf) has a marginal affinity 
to TfR [21]. So far, most of the studies have focused on 
the interaction between NAMI-A and apo-Tf as a poten-
tial drug transporter [22–24]; however, our approach con-
centrates on holo-Tf due to high affinity of iron-saturated 
form to TfR.
In this study, several issues were addressed: (1) the 
influence of the iron-occupied binding site on the overall 
association constant and Ru content in ruthenated Tf, (2) 
the competition in NAMI-A binding to Tf vs. HSA, and 
finally (3) the effect of low- and high-molecular-mass con-
stituents of human serum on NAMI-A binding to Tf. The 
investigation was carried out with the use of various serum 
models as well as human serum. A special care was under-
taken to use freshly prepared aqua solutions of NAMI-A 
to prevent its advanced hydrolysis undergoing at pH 7.4 
(dissociation of chlorido and dmso ligands) [25–28]. To 
determine the percentage of Ru content in proteins, the 
protein-unbounded Ru as well as ruthenated Tf and HSA 
were separated using fast protein liquid chromatography 
(FPLC). The ruthenium content was determined for the 
mineralized samples by the inductively coupled plasma 
mass spectrometry (ICP-MS), while the protein concen-
tration using the enzyme-linked immunosorbent assay 
(ELISA) specific for each protein.
Experimental
Chemicals
NAMI-A, (HIm)[trans-RuCl4(DMSO)(Im)] was prepared 
according to the previously reported procedure [30]. Its 
purity was checked by the elementary analysis. The analy-
sis calculated for NAMI-A (M = 458.17): C 20.95; H 3.30, 
N 12.23, S 6.99, found: C 21.37, H 3.33, N 12.03, S 6.90. 
Human apo-Tf and holo-Tf (powder, BioReagent, suitable 
for cell culture, ≥98 %), HSA (powder, fatty acids free, 
globulin free, ≥99 %) were obtained from Sigma-Aldrich 
(Germany). All used chemicals were obtained in the highest 
available purity from Sigma-Aldrich, POCH S.A. (Gliwice, 
Poland), Alfa Aesar (Massachusetts, USA) and Merck Mil-
lipore. Control human serum and normal level BioNorm 
were purchased from BioMaxima (Lublin, Poland). Human 
Tf ELISA (immunoperoxidase assay for determination 
of transferrin in sera) and HSA ELISA (immunoperoxi-
dase assay for determination of albumin) were obtained 
from ICL (Portland, USA). All solutions were prepared 
in MilliQ quality water, and eluents were filtered through 
0.45 μm membrane filters and degassed.
Samples preparation
The NAMI-A stock solutions were prepared by dissolving 
NAMI-A powder in MilliQ water and its concentration was 
determined spectrophotometrically using molar absorptiv-
ity at 390 nm of 3644 M−1 cm−1 as it was described pre-
viously [31]. All protein stock solutions were prepared by 
dissolving in an appropriate buffer and concentration was 
measured spectrophotometrically using absorption coeffi-
cients at 280 nm of 86,400, 84,000 and 42,000 M−1 cm−1 
for holo-, apo-Tf and HSA, respectively [32, 33]. In most 
of the experiments, the concentration of NAMI-A was 
Fig. 1  a Structure of NAMI-A. b Crystal structure of human serum 
holo-Tf showing the location of histidine residues (highlighted in 
blue) with solvent accessible surface, on the left and right front and 
back projection of Tf structure, respectively (PDB ID: 3QYT). This 
figure was made using PyMol [29]
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kept constant (0.70 mM) and it corresponds to the typical 
Ru concentration in the blood of patients within 24 h after 
treatment (0.4–0.8 mM Ru) [34]. Unless stated otherwise, 
the NAMI-A was kept at 20-fold excess over Tf. Serum 
Models 0 and 0* were prepared by mixing of proteins dis-
solved in 50 mM TRIS/HCl buffer pH 7.4 containing 0.1 M 
NaCl and 25 mM NaHCO3 at desired ratio (Fig. 4). Serum 
Models 1 and 2 were made by mixing components listed 
in Fig. 4 followed by pH adjusting to 7.4 and the addition 
of an appropriated amount of proteins. NAMI-A was added 
into all these models or into human serum by the addition 
of small volume of concentrated stock solution, usually 
2–5 μl. Samples with Ru complex were incubated 24 h at 
37 °C. Details concerning intermolecular competition stud-
ies are described in the caption of Table 1.
Spectrofluorimetric titration
Fluorescence measurements were performed on a spec-
trofluorimeter PerkinElmer LS55 equipped with the cir-
culation flow PolyScience thermostat in a quartz cell with 
a 1-cm path length. The emission spectra were recorded 
between 305 and 500 nm upon excitation at 295 nm. The 
average of three scans was subjected to smoothing and 
the fluorescence intensities were corrected due to dilution 
effects as previously described [22]. The fluorescence life-
time measurements were performed with a single photon 
counting technique using Fluorolog-3, Horiba JobinYvon. 
The excitation wavelength was set at 265 nm (NanoLed 
Diodes) and the lifetime of fluorescence was monitored at 
332 nm. Details are described in Ref. [22].
Separation of protein fractions
FPLC was applied to separate the mixture comprising the 
unbound ruthenium species, Tf–Ru adducts and HSA–Ru 
adducts. The chromatographic system ÄKTA Purifier 10 
and ÄKTA Pure (GE Pharmacia) with injection loop of 
100 μl or 1000 μl and fraction collector FRAC-901 were 
used for separation. The separation was monitored spec-
trophotometrically at 280 nm (Monitor UV-900, GE Phar-
macia) as well as by measuring the conductivity (Moni-
tor pH/C-900, GE Pharmacia). Anion exchanged MonoQ 
5/50 GL column (Tricorn, GE Healthcare Life Science; 
5 × 50 mm I.D., 10 μm particle diameter) was applied to 
the separation of ruthenated proteins. Solutions of 0.02 M 
BIS–TRIS/HCl pH 7.0, A, and 0.02 M BIS–TRIS/HCl, 1 M 
NaCl pH 7.0, B, were used as eluents. All samples were fil-
tered through 0.22 μm syringe filter before column applica-
tion. Separation conditions were used as follows: injection 
volume: 100 μl, target concentration of B: 50 %, gradi-
ent length: 20 column volumes (CV), flow rate: 1 ml/min. 
Afterwards, the separation column was washed with 5 CV 
of eluent B and re-equilibrated with eluent A, 5 CV. Alterna-
tively, the excess of Ru species was removed by membrane 
dialysis against 50 mM TRIS/HCl buffer pH 7.4 or water.
CaptureSelect™ Transferrin Affinity Matrix was used 
for a one-step transferrin purification from human serum. 
An empty column was packed with 2.5 ml of these res-
ins. The column was equilibrated with 10 CV of the equi-
libration buffer: PBS, pH 7.4. Serum was filtered through 
0.22 μm syringe filter and 400 μl of sample was injected 
into the column. Unbound serum components were washed 
with 5 CV of equilibration buffer. Transferrin was eluted 
with 5 CV of the elution buffer: 20 mM Tris, 50 % (v/v) 
propylene glycol, 1.0 M NaCl, pH 7.4 (chromatogram is 
presented in Fig. S1).
The abundance of proteins in human serum and after 
transferrin isolation by affinity chromatography was exam-
ined using 12.5 % polyacrylamide gel electrophoresis 
under denaturing conditions (SDS-PAGE) [35]. Gels were 
stained with Coomassie Brilliant Blue and documented 
using GelDoc-It™ 310 Imaging System (Upland, CA, 
USA).
Alternatively, the separation of protein fraction from 
low-molecular-mass components of human serum after 
incubation with NAMI-A was performed by ultrafiltration 
through a 3-kDa cutoff filter.
Determination of protein and ruthenium concentration
The Tf and HSA concentrations in the studied systems 
were determined using human Tf or HSA ELISA kits, 
respectively. Standard curves were prepared with the sup-
plied standards with concentration ranging from 9.375 to 
600 ng/mL for Tf and from 6.25 to 200 ng/mL for HSA. 
The tested samples were diluted appropriately in a sample 
diluent buffer and the tests were performed according to the 
manufacturer’s protocol. ELISA 96-well plates were read 
using Tecan Infinite 200 Reader plate at 450 nm for both Tf 
and HSA. The total protein concentration in human plasma 
was measured by Bradford method.
Table 1  Ru fraction [mol/mol(protein)] in ruthenated Tf or HSA pro-
duced after (1) incubation of NAMI-A, Tf and HSA at 1:1:1 molar 
ratio for 24 h in buffer; (2) incubation of HSA with 20 molar excess 
of NAMI-A, followed by purification by FPLC separation from free 
Ru species, and then mixed with Tf at 1:2 molar ratio
Buffer conditions: 50 mM TRIS/HCl, 100 mM NaCl, 25 mM 
NaHCO3, pH 7.4, 37 °C
Model Molar ratio Ru/Tf Ru/HSA
(1) holo-Tf/HSA/NAMI-A 1:1:1 0.39 ± 0.08 0.65 ± 0.07
apo-Tf/HSA/NAMI 1:1:1 0.24 ± 0.09 0.56 ± 0.06
(2) (HSA/NAMI)/holo-Tf (1:1):2 0.31 ± 0.02 0.67 ± 0.03
(HSA/NAMI)/apo-Tf (1:1):2 0.23 ± 0.02 0.71 ± 0.05
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The total Ru content in samples was measured by the 
application of ICP-MS using ELAN 6100 Perkin Elmer 
spectrometer. Prior to the determination of Ru content, 
100 μL of the samples was mineralized using 500 μl of 
Ultrapure concentrated nitric acid and then diluted with 
water.
The experiments were carried out at least in triplicate, 
unless stated otherwise.
Results and discussion
Affinity of NAMI‑A towards holo‑Tf
The quenching of intrinsic protein fluorescence upon ligand 
binding is a relatively quick and easy method for studying 
this interaction. The indole groups of tryptophan residues 
are the dominant source of UV absorbance and emission 
in proteins and its emission is sensitive to changes in the 
local microenvironment and can be used to monitor pro-
tein–ligand interactions [36]. Upon addition of NAMI-A 
to holo-Tf solution, the intensity of protein fluorescence 
gradually decreased and the reaction was completed within 
5 min (see Fig. 2). The reaction time was similar to that 
measured for apo-Tf; however, the relative fluorescence 
intensity of holo-Tf–NAMI-A adduct is much higher than 
for apo-Tf–NAMI-A. Taking into account that holo-Tf is 
‘closed’ iron-bound form, His and Trp residues are less 
accessible for NAMI-A so that the quenching is lower in 
comparison with apo-Tf.
A decrease in holo-Tf florescence was observed during 
NAMI-A addition in a concentration-dependent manner 
(Fig. 3). Ru complex addition caused the maximum emis-
sion shift towards longer wavelength from 338 to 346 nm. 
The observed red shift implies the formation of holo-Tf–Ru 
complex adduct that has more polar microenvironment in 
the vicinity of tryptophan residues. In apo-Tf, where Fe(III) 
ions are not present in binding sites the maximum of fluo-
rescence is at 332 nm while NAMI-A addition induced a 
shift to 338 nm [22]. The observed spectral changes sug-
gest that iron ion is not released upon NAMI-A complex 
binding, that was confirmed by ICP-MS measurements.
Fluorescence quenching data were analysed according 
to the Stern–Volmer equation [36]:
where F0 and F are the fluorescence intensities of holo-Tf 
in the absence and presence of quencher (Q, NAMI-A), 
respectively; kq is the bimolecular quenching constant; 
τ0 is the average lifetime of the holo-Tf fluorescence 
in the absence of quencher, [Q] is the concentration of 
quencher, KSV is the Stern–Volmer constant. The plot 
of F0/F versus [Q] was linear (compare Fig. 3 inset) up 
to almost 40-fold excess of Ru complex over holo-Tf. 
Based on Eq. (1), the calculated value of KSV was found 
to be 10 300 ± 100 M−1 at 37 °C. The measured value of 
the average lifetime of the holo-Tf in the absence of any 
quencher was ca. 2 × 10−9 s−1; therefore the calculated 
kq equals 5 × 1012 M−1 s−1. Such high value of the bimo-
lecular quenching constant points out the static quench-
ing and allows for consideration of the Stern–Volmer 




= 1+ kqτ0 · [Q] = 1+ KSV · [Q],
Fig. 2  Kinetics of holo-Tf fluorescence quenching by NAMI-A. 
Experimental conditions: [holo-Tf] = 2.0 μM, [NAMI-A] = 40 μM; 
Tris/HCl pH 7.4; [NaCl] = 0.1 M; [NaHCO3] = 25 mM, T = 37 °C; 
λex = 295 nm; λem = 338 nm
Fig. 3  Fluorescence emission spectra for holo-Tf in the presence 
of increasing concentration of NAMI-A. Inset Stern–Volmer plot 
showing the influence of the increasing concentration of NAMI-A 
on the fluorescence intensity of holo-Tf. Experimental conditions: 
[holo-Tf] = 2.0 μM, [NAMI-A] = 0–77 μM; Tris/HCl pH 7.4; 
[NaCl] = 0.1 M; [NaHCO3] = 25 mM; T = 37 °C λex = 295 nm; 
λem = 338 nm
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holo-Tf–Ru complex(es) adducts [22, 37].The association 
constant for holo-Tf is slightly lower than for apo-Tf (12 
800 ± 300 M−1) [22]. A moderate NAMI-A association 
constant for binding to holo-Tf can promote the release of 
Ru complex in cellular environment (e.g., at lower pH in 
lysosome) better than its liberation from apo-Tf–NAMI-A 
adduct. The obtained results indicate that Ru can bind not 
only to iron-binding sites like in apo-Tf, but also to other 
non-specific sites. Up to now, only X-ray structural stud-
ies on human lactoferrin (its structure closely matches 
that of human Tf) soaked with KP1019 (indazolium trans-
[tetrachlorobis(1H-indazole)ruthenate(III)]) are available 
in the literature and they showed the presence of two types 
of binding sites: a high affinity in N-lobe iron-binding cleft 
and lower affinity sites at surface exposed His residues 
[38]. They pointed out that His residues are important in 
Ru complexation. Tf possesses 17 His residues, many of 
which are exposed to the protein surface and accessible 
for solvent molecules, and are thus potential ruthenium-
binding sites (Fig. 1b). On the other hand, very recent in 
silico studies have shown that aquo-ethylenediaminetetraac
etatoruthenium(III) forms hydrogen bonds upon binding to 
apotransferrin [39].
Holo‑Tf‑bound Ru fraction
Holo-Tf was dissolved in buffer (50 mM Tris/HCl, 
100 mM NaCl, 25 mM NaHCO3, pH 7.4) and incubated 
with 20-fold excess of freshly prepared NAMI-A for 24 h 
at 37 °C, then injected into anion exchange MonoQ 5/50 
GL column for separation of free Ru species from holo-
Tf-bound one (Fig. S2). Ru content in holo-Tf-bound frac-
tion was quantified using ICP-MS method, while holo-Tf 
concentration was determined using ELISA. The Ru frac-
tion [mol/mol(holo-Tf)] in ruthenated holo-Tf adducts was 
found to be 1.3 ± 0.1. It can be presumed that holo-Tf is 
able to bind at least one Ru ion, probably with moderate 
affinity; however, the binding of additional Ru ion with 
lower affinity cannot be excluded. Moreover, the presented 
data proved that ruthenated holo-Tf adduct was stable 
enough to be separated from free Ru species, suggesting 
the irreversible type of interaction under employed experi-
mental conditions. This assumption was also supported by 
the determination of similar holo-Tf-bound Ru fraction 
after 24 h of membrane dialysis against either buffer or 
water. Our measurements using ICP-MS method as well 
as previously published data [40, 41] indicate that Ru ion 
does not replace iron in binding sites. Interestingly, even 
though the binding site in holo-Tf is occupied by iron, still 
holo-Tf offers better environment for binding of NAMI-
A, which in case of apo-Tf was found to be at last two 
times lower (<0.6) [22]. This can arise from substantial 
structural differences between apo and holo forms of Tf, 
which, in turn, influence on His residue accessibility for 
Ru binding.
Intermolecular competition studies: Tf versus HSA
NAMI-A affinity to both Tf and HSA was checked by anal-
ysis of Ru distribution between these proteins. To this end, 
two types of experiments were performed. Tf, HSA and 
NAMI-A were mixed at 1:1:1 molar ratio and incubated 
for 24 h in buffer at 37 °C. Then the mixture was sepa-
rated on the MonoQ column (see Fig. S3), protein fractions 
were collected and Ru content per proteins was measured 
using ICP-MS and ELISA techniques. While NAMI-A 
interacted with HSA and Tf at the same concentration, a 
slightly higher amount of Ru was bound to HSA than to Tf 
(see Table 1). The NAMI-A complex had a slightly lower 
affinity towards apo- versus holo-Tf, and also more pro-
tein-unbound Ru species remained in solution containing a 
Fig. 4  a Purification of [HSA–Ru] adduct from a mixture of HSA 
and NAMI-A incubated at 1:1 molar ratio for 24 h in buffer. b Sepa-
ration of ruthenated proteins (holo-Tf and HSA) after addition to 
[HSA–Ru] adduct holo-Tf at 1:2 molar ratio and incubation for 24 h 
in buffer. Asterisk denotes the peak from solvent front comprising 
unbound Ru species. Buffer conditions: 50 mM TRIS/HCl, 100 mM 
NaCl, 25 mM NaHCO3, pH 7.4; 37 °C
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mixture of HSA with apo-Tf. This further supports assump-
tion that NAMI-A complex binds to holo-Tf with higher 
extent.
Alternatively, NAMI-A was incubated with HSA at 
molar ratio 20:1 for 24 h at 37 °C, and then the HSA–Ru 
adduct was separated from free Ru species on the MonoQ 
column (see Fig. 4a). To the purified HSA–Ru adduct frac-
tion, two molar excess of Tf over HSA was added and the 
mixture was incubated for 24 h at 37 °C. Subsequently, 
the ruthenated proteins were separated (see Fig. 4b) and 
Ru fraction in both types of adducts was assessed and the 
results are summarized in Table 1. The analysis of ruthe-
nium distribution shows that both apo- and holo-Tf are able 
to sequester Ru ions from HSA, though albumin is still the 
major location of Ru ions. It was proposed for Pt-based 
drugs that platinated HSA can act as a Pt storage system 
[42]. One can assume by analogy that ruthenated HSA can 
serve as a reservoir of Ru ion for Tf in case of NAMI-A 
complex.
Ru distribution in serum models
To achieve a better insight into NAMI-A behaviour in 
biological environment, Ru distribution between Tf and 
HSA was analysed in three types of serum models whose 
composition is presented in Fig. 5. The simplest Model 0 
comprised the physiological mixture of Tf (30 % of holo 
and 70 % of apo forms [18]) and HSA at concentrations 
typically found in human serum dissolved in physiologi-
cal type buffer (pH 7.4). It was used to clarify the impact 
of high HSA excess on Ru binding to Tf. For comparison, 
the Model 0*, possessing Tf only fully saturated with iron 
was also included. Serum Models 1 and 2 were prepared 
based on the composition proposed by Harris [43] and used 
by other researchers [44, 45] with slight modifications (see 
Fig. 5). Model 1 was composed of amino acids with (Cys, 
His, Glu) or without (Gly, cysteine) additional coordinating 
group, inorganic (chloride, carbonate, phosphate, sulphate) 
and organic (oxalate) sodium salts, lactic and citric acids, 
as well as the same content of proteins like in Model 0, all 
adjusted to pH 7.4. Model 2 had the same components as 
1, however, was enriched with metal ions: calcium, magne-
sium and zinc.
NAMI-A at 20-fold excess over Tf (0.7 mM) was incu-
bated with all these serum models for 24 h at 37 °C and 
then the reaction mixture was injected onto MonoQ column 
to separate unbound Ru species from those bound to Tf and 
HSA. The obtained chromatographs are presented in Fig. 6.
As can be seen in Table 2 Ru distribution varies 
between applied models. In Model 0* and Model 0, holo-
Tf showed very similar binding properties pointing out that 
introducing apo form has a marginal impact on ruthena-
tion of Tf. The presence of 18-fold excess of HSA over 
Tf has a distinct influence on holo-Tf–Ru adduct forma-
tion, lowering it by factor ca. two. Taking into account the 
fact that one molecule of HSA can bind ca. one and half 
Ru equivalent (data taken from [26]) all added Ru com-
plex could be consumed by HSA. However, the obtained 
data proved that holo-Tf can readily compete in binding 
of Ru species. This very well correlates with data obtained 
from the intermolecular competitive binding studies show-
ing that both proteins are ruthenated under deficiency of 
Ru complex (see Table 1). Calculation of the whole Ru 
distribution showed that in these two models, ca. 40–50 % 
of Ru species remained in the unbound form, despite equi-
molar concentration of NAMI-A and proteins. The addi-
tion of low-molecular-weight components of human serum 
included in Model 1 gave rise to evident increase in frac-
tion of Ru equivalents in both proteins, while the frac-
tion of free Ru species was negligible. The enhancement 
of Ru species binding to serum proteins can arise from 
transformation of NAMI-A into more active Ru species 
or/and modulation of protein surface making the binding 
sites more accessible. For instance, the reducing agent like 
cysteine could change the oxidation state of Ru or serve as 
a S-donor ligand. Moreover, N-donor ligands like His, or 
O-donors: Glu, oxalate, citrate and lactate can from other 
Ru complexes with higher binding affinity to serum pro-
teins. Furthermore, in Model 2, where additionally Ca2+, 
Zn2+ and Mg2+ were included, Tf-bound fraction of Ru 
was even higher than in serum-like conditions without 
the addition of metal ions. The Ru fraction bound to HSA 
Fig. 5  Serum models’ composi-
tions (pH 7.4)
Tf 35 μM
(30% apo, 70% holo)
*(100% holo)
HSA 630 μM








lactic acid 1.51 mM
sulphate 3.3 mM
phosphate 1.1 mMGly 2.3 mM
NaCl 145 mM
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stayed on the similar level, while the fraction of free Ru 
species was minor. The introducing of metal ions did not 
decrease Ru binding, but, on the contrary, Tf-bound form 
was even more abundant. One can assume that they do not 
compete with Ru species in binding to Tf, what is more, 
they can influence the accessibility of Ru-binding sites by 
non-specific interaction with Tf. The crystal structure of 
Tf with Ca2+, Mg2+ and Zn2+ ligands is unknown and Tf 
does not have a primary role in the distribution of mag-
nesium, copper, or zinc to tissues [46]. These interesting 
results need further clarification; however, it is beyond the 
scope of this work. In summary, the presence of only very 
small fraction of unbound Ru species in Model 1 and 2 
indicates the high affinity of NAMI-A towards both serum 
proteins (HSA, Tf) and despite the presence of much 
higher amount of HSA over Tf still the formation of Tf–Ru 
adducts is feasible under physiological concentration of 
these proteins.
NAMI‑A interaction with human serum
The relevant physiological conditions have been achieved 
by application of human serum. Incubation of NAMI-A with 
human serum (20-fold excess of Ru complex over Tf) was 
performed over 24 h at 37 °C, and then Tf and ruthenated 
Fig. 6  MonoQ chromato-
graphic separation of serum 
models incubated with the 
20-fold excess of NAMI-A over 
Tf for 24 h at 37 °C. a Model 
0*, b Model 0, c Model 1 and 
d Model 2 (compositions are 
described in Fig. 5). Asterisk 
denotes the peak from solvent 
front comprising unbound Ru 
species. The elution conditions 
were described at the experi-
mental part
Table 2  Ru fraction [mol/mol (protein)] in ruthenated Tf or HSA 
produced after incubation of NAMI-A, Tf and HSA at 20:1:18 molar 
ratio for 24 h at 37 °C in various models of serum (the composition is 
depicted in Fig. 5)
Model Tf saturation (%) Ru/Tf (mol/mol) Ru/HSA (mol/mol)
0* 100 0.50 ± 0.08 0.50 ± 0.06
0 30 0.52 ± 0.07 0.51 ± 0.05
1 30 2.0 ± 0.2 1.2 ± 0.1
2 30 2.9 ± 0.5 1.1 ± 0.1
Fig. 7  SDS-PAGE electrophoresis. Line 1 protein marker; lines 2, 
3 and 4 human serum diluted 10, 20 and 30 times, respectively; line 
5 human serum transferrin (Sigma-Aldrich) 40 μg; line 6 unbound 
fraction of serum eluted from Capture Select resins; line 7 elution 
fraction from Capture Select resins
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Tf were isolated using affinity chromatography resins (see 
Fig. S1). The efficiency of affinity column was checked by 
SDS-PAGE analysis (Fig. 7). SDS-PAGE gel showed that 
after elution only Tf was present. In separated Tf fraction, 
Ru and Tf concentrations were determined using ICP-MS 
and ELISA techniques, respectively. The analysis showed 
that 0.37 ± 0.03 mol of Ru was bound per mole of Tf. The 
presence of low-molecular-mass components of serum 
Models 1 and 2 increased Ru binding; however, in biologi-
cal environment of blood, other proteins like immunoglobu-
lins and fibrinogen can compete with Tf in binding of Ru 
species lowering the ruthenated Tf fraction. To verify if the 
macromolecules present in the serum can become a poten-
tial targets for NAMI-A, the overall amount of Ru species 
bound to proteins was assessed using ultrafiltration as a sep-
aration method. The mixture of NAMI-A and human serum 
incubated under the same conditions as previously, was 
centrifuged through the 3 K MWCO cutoff filter and both 
ultrafiltrate and protein fractions were collected for ICP-MS 
analysis. The fraction of Ru bound to proteins was found to 
be of 98 % (2 µg of Ru/1 mg of protein) proving that most 
of the Ru species exist in protein-bound form, and that the 
decrease of Ru in Tf fraction arises from binding to other 
proteins. These results are consistent with the data obtained 
from human clinical trials [34] as well as studies on combi-
nation therapy involving cisplatin and NAMI-A [47].
Conclusions
To summarize, it was demonstrated that NAMI-A can bind 
to holo-Tf as readily as to apo-Tf without effecting iron 
content in this protein. In addition, the competition experi-
ments showed that the affinity towards two serum proteins, 
namely HSA and transferrin is very similar. Although the 
concentration of HSA in human plasma is much higher than 
Tf, the ruthenated Tf was still detected under physiological-
like conditions. Studies on serum models clearly showed 
the strong influence of low-molecular-mass components of 
serum on Ru complex binding to Tf. The additional pro-
teins present in human serum effectively competed in Ru 
complex binding lowering the fraction of ruthenated Tf. 
In general, it was proved that protein-bound Ru forms 
are major metabolites of NAMI-A after administration to 
human serum. The presented results indicate that careful 
attention should be given to performing experiments under 
conditions better simulated real physiological environment. 
Presuming that ruthenated holo-Tf might be one of NAMI-
A complex metabolites, further investigations on interac-
tion of this adduct with TfR and its taking up into the cells 
via endocytosis seem to be rational research issue.
Electronic Supplementary Information (ESI): Affin-
ity chromatography isolation of Tf from human serum, 
MonoQ chromatographic separation of holo-Tf incubated 
with NAMI-A, or HSA and Tf with NAMI-A at 1:1:1 
molar ratio.
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